The United Laboratories International Holdings Limited

中/EN
中文繁體 English
  • Investor Relations
    IR Home Corporate Overview Financial Highlights Financial Reports ESG Reports Regulatory Filings Press Releases Company Presentations Stock Quotes & Charts Analyst Coverage FAQs IR Contact
  • Corporate
Investor Relations
  • IR Home
  • Corporate Overview
  • Financial Highlights
  • Financial Reports
  • ESG Reports
  • Regulatory Filings
  • Press Releases
  • Company
    Presentations
  • Stock Quotes &
    Charts
  • Analyst Coverage
  • FAQs
  • IR Contact

Press Releases

2017
Please select
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
AUG
24
The United Laboratories International Holdings Limited Recorded A Turnaround with Profit in 2017 Interim Results, Maintained Outstanding Sales Performance of Recombinant Human Insulin Injection Products Officially Launched Insulin Glargine Injection to Drive Sales Growth in the Future
MAY
14
"United Laboratories USLEN" Insulin Glargin Gained Experts' Recognition and Recommendation, Successfully Won the Tender Through Bidding in Four China Provinces and Products are to be Rolled Out Gradually
MAR
23
The United Laboratories International Holdings Limited Announces 2016 Annual Results, Maintained Outstanding Performance of Recombinant Human Insulin Injection Products, Gained Approval to Produce Insulin Glargine for Injection and Drive Sales in the Future
Disclaimer | Sitemap

Copyright © 2019 The United Laboratories International Holdings Limited. All rights reserved.